Moximed has raised $151.0M in total across 3 funding rounds.
Moximed's investors include Advent Life Sciences, SR One.
Moximed is a medical device company developing the MISHA Knee System, an implantable shock absorber (ISA) for treating medial compartment knee osteoarthritis (OA) in active patients who have not found relief from non-surgical or surgical options.[1][2][8] The device reduces peak knee forces by over 30% with every walking step, easing pain, preserving joint function, and potentially delaying total knee replacement, serving patients with mild to moderate OA who want to maintain active lifestyles.[1][2][4][9] Founded in 2008 and based in Fremont, California, Moximed has raised over $150 million in funding, including a $91 million Series D, achieved FDA clearance, and begun commercial treatments in the US as of 2023, with strong surgeon and patient interest driving growth.[1][2][4]
Moximed was founded in 2008 by Anton Clifford, Ph.D., who serves as CEO, recognizing the unmet need for load management in early knee OA treatment—an opportunity others overlooked.[2][6] The company emerged from insights into joint unloading's benefits, initially developing systems like the Atlas™ (available in Europe), and evolved through over a decade of clinical research, surgeon collaboration, and persistence to create the polymer-based MISHA Knee System by 2014.[5][6] Pivotal moments include superior primary endpoint results in a 2022 pivotal study presented at the Orthopaedic Summit, FDA clearance, and the first US commercial implants in September 2023, marking a shift from R&D to commercialization.[1][2]
Moximed rides the trend of joint-preserving therapies in orthopedics, addressing the growing knee OA market affecting millions, where traditional options like total knee replacement are invasive and unsuitable for younger, active patients.[1][2][4] Timing aligns with aging populations, rising OA prevalence, and demand for non-replacement alternatives, amplified by clinical validation and FDA clearance amid a shift toward personalized, minimally invasive medtech.[1][2] Favorable market forces include surgeon education focus, commercial momentum post-2023 launches, and investor confidence via major financings, positioning Moximed to influence standards of care by expanding access and potentially reducing healthcare costs through delayed surgeries.[2][4]
Moximed is set for scaled commercialization, leveraging $91M Series D to build infrastructure, educate surgeons, and meet surging demand from US academic and private practices.[2][4] Trends like value-based care, active aging demographics, and advances in biomaterials will propel growth, with MISHA potentially becoming standard for medial OA before arthroplasty.[1][2] Its influence may evolve by pioneering ISA platforms beyond knees, redefining OA management and enabling healthier, longer active lives for millions—transforming chronic pain from a joint-ending sentence to a manageable step.
Moximed has raised $151.0M across 3 funding rounds. Most recently, it raised $61.0M Series D in August 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2024 | $61.0M Series D | Advent Life Sciences, SR One | |
| Aug 1, 2022 | $40.0M Series C | Advent Life Sciences, SR One | |
| Mar 1, 2017 | $50.0M Series C | Advent Life Sciences, SR One |
